NAFDAC Issues Public Alert on Counterfeit Pharmaceutical Product

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert regarding a counterfeit pharmaceutical product found in circulation. The alert specifically addresses a fake version of Augmentin 625mg tablets, a commonly prescribed antibiotic.

Details of the Counterfeit Product

The counterfeit product identified is Augmentin 625mg tablets, manufactured by GlaxoSmithKline (GSK). NAFDAC has stated that the product currently in circulation is not genuine. Consumers and healthcare professionals are urged to be vigilant and to report any findings of this specific counterfeit medication.

Action and Recommendations

NAFDAC is taking steps to remove the counterfeit product from the market and prevent further distribution. The agency advises the public to exercise caution when purchasing and using pharmaceutical products. It is recommended that all Augmentin 625mg tablets be verified for authenticity. Healthcare practitioners and distributors are particularly encouraged to ensure that the products they dispense are legitimate and sourced from authorized channels.

In conclusion, NAFDAC has alerted the public to a counterfeit version of Augmentin 625mg tablets. The agency is working to address the issue and urges vigilance in identifying and reporting fake medications.